Table 2.
Echocardiographic characteristics of patients at baseline
| Alendronate treated | Nontreated | P# | Adjusted mean difference | L | U | Adjusted P$ | |
|---|---|---|---|---|---|---|---|
| LVDD (mm) | 46.27±5.04 | 46.48±4.43 | 0.70 | −0.11 | −2.45 | 2.24 | 0.928 |
| LVEF (%) | 56.86±4.78 | 57.03±3.94 | 0.86 | −0.32 | −2.40 | 1.76 | 0.758 |
| IVS (mm) | 11.75±1.90 | 11.18±1.94 | 0.19 | 0.55 | −0.41 | 1.51 | 0.254 |
| MG (mmHg) | 22.81±9.09 | 24.87±8.04 | 0.18 | −2.90 | −6.99 | 1.19 | 0.161 |
| PG (mmHg) | 39.87±14.82 | 42.10±11.04 | 0.48 | −3.70 | −9.83 | 2.43 | 0.233 |
| AVA (cm2) | 1.46±0.35 | 1.57±0.33 | 0.22 | −0.07 | −0.23 | 0.10 | 0.404 |
LVDD=Left ventricular diastolic diameter; LVEF=Left ventricular ejection fraction; IVS=Interventricular septum; MG=Mean gradient; PG=Peak gradient; AVA=Aortic valve area. Data are expressed as mean±SD. #Based on t-test; $Adjusted for age, BMI, and follow-up time using analysis of covariance; L=95% confidence interval lower bound; U=95% confidence interval upper bound; BMI=Body mass index